50results about How to "Expansion of medical use" patented technology

The invention relates to a medicinal composition for treating an ischemia reperfusion injury, particularly a hepatic ischemia reperfusion injury, and a preparation method and application thereof. The composition comprises an M-cholinergic receptor blocker and a cholinesterase inhibitor, has a simple and convenient preparation process, is safe to use, has an obvious curative effect, can be used for obviously improving the cell apoptosis caused by the ischemia reperfusion injury and overcomes the side effects caused by existing common medicaments. The invention expands novel medical application of an existing muscarinic receptor blocker and also provides a novel medicine intervention means for preventing and treating the ischemia reperfusion injury. The medicinal composition is suitable for large-scale production and commercial application in the industries of medicine, reagents and the like, has excellent application prospect and has obvious social benefits and economic benefits.

The invention discloses an application of compound of timosaponin extract in foods and preparation of prostate hyperplasia medicine in medicine and pharmacology technical domain, which is characterized by the following: possessing saponin and chromocor chemical element in timosaponin; possessing anti-diabetes medicinal and antibiotic function; setting the sum of mango glycosides and new mango glycosides content not less than 50%. This invention also discloses a basic preparing method. This invention can be used to cure big mouse prostate hyperplasia of enarmon, which can prepare medicine to prevent and cure prostate hyperplasia.

The invention relates to application of polydatin which is an extract of polygonum cuspidatum. In-vitro researching experiments show that the polydatin has strong protecting effect for pathological injuries caused by rats multiple infarctional cerebral ischemic injuries, can significantly improve learning memory function of dementia model rats, so the polydatin can be used for preparing a product for resisting vascular dementia and a product, particularly a medicine for resisting senile dementia. The modes for using the polydatin include independent use, or combined use with other chemical substances. Dementia is a key disease impacting health of the elderly, particularly, frequency of disease development of the vascular dementia and the senile dementia is significantly increased to seriously threaten health and life of human beings. The invention provides a novel drug source for clinically treating the vascular dementia and the senile dementia, and has important value for developing and utilizing medicinal plant resource in China.

The invention discloses a humanized CD20-resistant monoclonal antibody. A heavy chain variable region of the humanized CD20-resistant monoclonal antibody has an amino acid sequence as follows: VH: SEQ ID:NO.6; and a light chain variable region has an amino acid sequence as follows: VL:SEQ ID:NO.8. The invention further comprises an application of the monoclonal antibody to the aspects of researches as well as diagnosis and treatment. The invention provides the humanized CD20-resistant monoclonal antibody with high specificity. Compared with a positive medicament, the monoclonal antibody has the advantages of better medicinal effect, simple and convenient preparation process, lower cost, wide application range, and capability of meeting the social requirements, and supplies an accurate, easy, convenient and effective monitoring means for the prevention, treatment, early-stage screening and diagnosis work of cancers and eye diseases. Above all, the CD20-resistant monoclonal antibody positively adapts to the working requirements and the requirement of user-friendly service in the fields of modern biology, prevention and health care, clinical diagnosis and the like; the humanized CD20-resistant monoclonal antibody is researched and developed to provide a treatment medicament with higher cost performance for the medicament market in China; and the CD20-resistant monoclonal antibody has a very wide application prospect.

The invention discloses a traditional Chinese medicine composition which is prepared from the following raw materials: xanthium strumarium, rhizoma imperatae, violet magnolia, radix ophiopogonis, radix angelicae, liquorice, luffa stems, dried radix rehmanniae and honeysuckle flowers. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention has the advantages of short responding time, safety, nontoxicity, low price and practicability, is applicable to most people, takes effect quickly and is convenient to use.

The invention relates to the technical field of medicines, healthcare products and the like, and particularly to a new application of procyanidine B2 related to active Chinese medicine components in preparation of products, especially medicines and healthcare products for preventing, diagnosing, detecting, protecting, treating and researching vascular dementia, alzheimer disease and diseases directly related to vascular dementia and alzheimer disease. Experiments prove that the procyanidine B2 can enhance the learning and memory capabilities of a mouse with vascular dementia caused by global cerebral ischemia reperfusion injury, a rat with vascular dementia caused by cerebral ischemia reperfusion injury, and a rat with alzheimer disease caused by beta amyloid protein. The compound is strong in action, obvious in effect, abundant in source, stable in property, safe in use, especially wide in use range, and capable of furthest exerting the action thereof. The incidence rate of dementia continuously rises, and the new applciation of procyanidine B2 can generate remarkable social benefits and economic benefits in a short time after being popularized.

The invention relates to an anti-CD20 monoclonal antibody, a preparation method and an application of the anti-CD20 monoclonal antibody; Chinese hamster ovary cells CHODG44 are adopted to prepare the anti-CD20 monoclonal antibody consistent to rituximab, thereby establishing a large-scale high-expression production technology for 300L of eukaryocytes, wherein the protein expression quantity is more than 1.2g / L and the protein purification yield is improved to more than 60%. The anti-CD20 monoclonal antibody is safe, effective, relatively strong in practicability, low in cost, convenient and quick, and the preparation technology of the anti-CD20 monoclonal antibody is simple and convenient, easy to operate and use and obvious in curative effect, thereby providing a new source of medicines for the B cell induced malignant tumors, particularly the non-hodgkin lymphoma, autoimmune disease, renal failure, hepatitis B, hepatitis C and diabetes, etc.; the anti-CD20 monoclonal antibody is applied to the large-scale production and commercial application in the industries such as medicine, biotechnology and the like and has a good application prospect, remarkable social benefit and economic benefit.

The invention relates to a traditional Chinese medicine extract with adenosine deaminase inhibition activity and an application of the traditional Chinese medicine extract. A preparation method of thetraditional Chinese medicine extract comprises the steps of taking traditional Chinese medicinal material powder, adding methanol, performing ultrasound extraction under a sealed condition, after theultrasound extraction, complementing the lost weight with methanol, performing centrifugation, taking a supernate, performing nitrogen blow-drying to form an extract, namely the traditional Chinese medicine extract, wherein traditional Chinese medicines are radix bupleuri, ligusticum wallichii, Chinese angelica, radix sophorae flavescentis, artemisia capillaris, bighead atractylodes rhizome, folium isatidis, a glossy privet fruit, schisandra chinensis, gardenia, rheum palmatum, sinensis, rhizoma cimicifugae, pollen pini, polygonum cuspidatum or sedum sarmentosum. After determination by established liquid chromatography-tandem mass spectrometry, the traditional Chinese medicine extract has a stronger inhibiting effect on adenosine deaminase, and cell experiments and animal experiments further confirm that the traditional Chinese medicine extract has a significant treatment effect on leukemia and the like.

The invention discloses application of 4-hydroxyl-2-pyridone alkaloid in preparing an antitumor product. The 4-hydroxyl-2-pyridone alkaloid is Sambutoxin, and a chemical structure of the 4-hydroxyl-2-pyridone alkaloid is shown in the description. Through researches of animal experiments, cell experiments and the like, the compound is shown to have very strong antitumor activity on varieties of tumor cells including lung cancer, cervical cancer, colon cancer and breast cancer; the compound has the advantages of obvious effects, safety, low toxin, convenience in use and rich and cheap raw material sources; a preparation technology has the advantages of simpleness, high yield, stable characters, convenience in quality control, lower production cost and convenience in application production; anovel medicine source and a safe raw material are provided for treating and researching antitumor and direct related diseases of the antitumor.

The invention relates to a melamine antigen, a related antibody and a preparation method thereof. Melamine and carrier protein are coupled by using PAD (polyaldehyde dextran) as bridge reagent; coupling products is used to immunize animals to prepare monoclonal antibodies for detecting melamine. Artificially-prepared melamine antigen and related antibody provided by the invention can be used for researching and developing melamine immunity detection reagents to meet detection demand on low cost, rapidity and convenient operations.

The invention discloses the application of the total polysaccharide of Platycodon grandiflorum in preparing a medicine for treating cell apoptosis induced by CCCP. The invention uses CCCP to establish a cell apoptosis model caused by mitochondrial pathway, and studies the effect of Platycodon grandiflorum total polysaccharide on cell activity and cell apoptosis after CCCP induces oxidative damage in porcine alveolar macrophages. The present invention finds for the first time that a certain concentration of Platycodon grandiflorum total polysaccharide (100-200 μg / mL) can antagonize cell apoptosis caused by CCCP, significantly reduce the phenomenon of nuclear deformation, and inhibit the change of mitochondrial membrane potential. The invention expands the medical application of the total polysaccharide of Platycodon grandiflorum, and is beneficial to the development of medicines with new indications that use the total polysaccharide of Platycodon grandiflorum as an effective ingredient.

The invention discloses application of anthocyanin in preparation of drugs for treating cell injury caused by arsanilic acid. An in-vitro chick embryo fibroblast DF-1 cell model is established for studying application of arsanilic acid and anthocyanin in apoptosis of DF-1 cells. The application of arsanilic acid and the anthocyanin in apoptosis of the DF-1 cells firstly discovers that arsanilic acid has cytotoxicity on the DF-1 cells and is capable of inducing the apoptosis. The anthocyanin with a certain concentration being 50-100 micrograms per milliliter can resist the apoptosis caused by arsanilic acid; the medical application of the anthocyanin is expanded; the development of drugs taking the anthocyanin as an effective component and having new indications can be facilitated.